PATENT CLAIM ANALYSIS

Application Number: 15941030
Application Type: Utility
Filing Date: 2018-03
Publication Date: 2018-10
Patent Classification: ["514", "006700"]

Abstract:
The present invention provides a novel peptide compound having an activating action on GIP receptors and use of the peptide compound as a medicament. Specifically, a peptide containing a sequence represented by the formula (I) or a salt thereof and a medicament comprising the same are provided. P 1 -Tyr-A2-Glu-Gly-Thr-A6-A7-A8-A9-A10-A11-A12-A13-A14-A15-A16-A17-A18-A19-A20-A21-A22-A23-A24-A25-A26-A27-A28-A29-A30-A31-A32-A33-A34-A35-A36-A37-A38-A39-A40-P 2    (I) wherein each symbol is as defined herein.

Claim (Index 4):
The peptide according to  claim 1  represented by formula (IV):\n P 1 -Tyr-Aib-Glu-Gly-Thr-A6-A7-A8-A9-A10-A11-A12-A13-A14-A15-A16-A17-A18-A19-A20-A21-A22-A23-A24-A25-A26-A27-A28-A29-A30-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-A40-P 2  (SEQ ID NO: 168) \n wherein \n P 1  represents a group represented by formula \n \u2014R A1 , \n \u2014CO\u2014R A1 , \n \u2014CO\u2014OR A1 , \n \u2014CO\u2014COR A1 , \n \u2014SO\u2014R A1 , \n \u2014SO 2 \u2014R A1 , \n \u2014SO 2 \u2014OR A1 , \n \u2014CO\u2014NR A2 R A3 , \n \u2014SO 2 \u2014NR A2 R A3 , or \n \u2014C(\u2550NR A1 )\u2014NR A2 R A3  \n wherein R A1 , R A2 , and R A3  each independently represent a hydrogen atom, an optionally substituted hydrocarbon group, or an optionally substituted heterocyclic group; \n P 2  represents \u2014NH 2  or \u2014OH; \n A6 represents Iva, Phe, or Val; \n A7 represents Ile or Val; \n A8 represents Ser; \n A9 represents Asp or Leu; \n A10 represents Tyr; \n A11 represents Aib or Ser; \n A12 represents Ile; \n A13 represents Aib, Ala, or D-Iva; \n A14 represents Leu; \n A15 represents Asp; \n A16 represents Arg; \n A11 represents Aib, Gln, or Ile; \n A18 represents Ala or His; \n A19 represents Gln; \n A20 represents Aib, Ala, or Gln; \n A21 represents Glu, Asn, Asp, or Ser; \n A22 represents Phe or aMePhe; \n A23 represents Val; \n A24 represents Arg, Asn or Asp; \n A25 represents Trp; \n A26 represents Leu or Iva; \n A27 represents Leu; \n A28 represents Ala or Arg; \n A29 represents Gln or Gly; \n A30 represents Arg or Gly; \n A40 represents Arg or a deletion; and \n any one or two amino acids selected from A8 to A30 optionally represent Lys(R), and R represents a substituent group, \n or a salt thereof.

Metadata:
- Claim Count in Document: 2.0
- Percentile: 90.0
- Lexical Diversity: 1.36735
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['16303975', '14780579', '14125061', '14800627', '14287514']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8538469257331377
- 35 USC 102 Novelty (BERT): 0.6268955175500733
- Combined Prediction Score: 0.8311517849148313
- Mean Citation Score: 634.65795
- Max Citation Score: 721.8596
- Similarity Product: 494.58909487075806

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test